In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Tetragon Partners GP Ltd reported 32 stock positions worth $614.3 million . Its top holding was Uipath Class A (PATH) at 54.8% of the portfolio, followed by Kolibri Global Energy (KGEI, 5.5% ) and Autolus Therapeutics (AUTL, 2.5% ). Compared with Q1 2026, it opened 5 new positions, sold out of 7, added to 15 and reduced 5. The biggest buy was a new position in Alkami Technology (ALKT) and the biggest sale Warner Bros Discovery (WBD, shares −73% ).
Location GRAND CAYMAN, E9
CIK 0001515070
Portfolio Value $614.3M (Q2 2026) Holdings 32 stocks · $614.3M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2026 PATH Uipath Inc. Class A 30,950,000 $336.4M Add +22.8% KGEI Kolibri Global Energy Inc. 6,834,504 $33.8M No change AUTL Autolus Therapeutics PLC 9,500,000 $15.2M No change LYFT LYFT Inc. Class A 1,000,000 $14.6M No change DFTX Definium Therapeutics Inc. 286,990 $13.5M Add +43.5% WK Workiva Inc. 250,000 $12.1M No change CXM Sprinklr Inc. Class A 2,200,000 $11.4M No change MBX MBX Biosciences Inc. 203,543 $11.2M Add +39.9% ALKT Alkami Technology Inc. 600,284 $10.9M New CLDX Celldex Therapeutics Inc. 290,441 $10.8M Reduce -7.0% RLAY Relay Therapeutics Inc. 570,311 $10.7M Add +214.2% ARWR Arrowhead Pharmaceuticals Inc. 130,484 $10.6M Add +2.6% PHVS Pharvaris NV 295,627 $10.2M Add +33.4% ALKS Alkermes PLC 189,979 $10.0M Add +18.9% IMVT Immunovant Inc. 255,934 $9.9M Add +17.1% SLN Silence Therapeutics PLC-ADR 764,256 $8.4M Add +21.3% DYN Dyne Therapeutics Inc. 356,657 $7.9M Add +38.2% IONS Ionis Pharmaceuticals Inc. 97,173 $7.7M Add +132.7% AGIO Agios Pharmaceuticals Inc. 205,579 $7.6M Add +24.7% HRMY Harmony Biosciences Holdings 201,036 $7.3M Add +68.5% KRYS Krystal Biotech Inc. 19,668 $7.3M No change ANNX Annexon Inc. 1,242,455 $7.1M Reduce -3.9% CELC Celcuity Inc. 64,110 $6.7M New WBD Warner Bros Discovery Inc. 250,000 $6.7M Reduce -72.9% NKTR Nektar Therapeutics 86,996 $6.1M Reduce -15.6% AMLX Amylyx Pharmaceuticals Inc. 297,926 $5.4M Reduce -6.3% ACAD Acadia Pharmaceuticals Inc. 167,875 $4.2M Add +16.1% CUE Cue Biopharma Inc. 93,819 $3.0M New SNOW Snowflake Inc. 10,000 $2.5M No change ACRS Aclaris Therapeutics Inc. 400,000 $2.1M New TECX Tectonic Therapeutic Inc. 46,516 $1.6M Add +23.8% GLUE Monte Rosa Therapeutics Inc. 56,052 $1.4M New
Options reported separately and not counted above: AXSM calls ($8.6M), RARE calls ($3.3M), SLN calls ($3.3M), KPTI calls ($2.4M), AGIO calls ($1.9M), TENX calls ($1.1M), AMLX calls ($153K).
Portfolio Sells Q1 2026 → Q2 2026 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2026 % Of Portfolio Change To Portfolio ▲ WBD Warner Bros Discovery Inc. Reduce -72.9% 1.08% −3.90 PRAX Praxis Precision Medicines I Sold out 0.00% −1.01 SLNO Soleno Therapeutics Inc. Sold out 0.00% −0.67 AXSM Axsome Therapeutics Inc. Sold out 0.00% −0.67 NKTR Nektar Therapeutics Reduce -15.6% 0.99% −0.47 MPLT Maplight Therapeutics Inc. Sold out 0.00% −0.45 ANNX Annexon Inc. Reduce -3.9% 1.15% −0.25 AARD Aardvark Therapeutics Inc. Sold out 0.00% −0.23 CLDX Celldex Therapeutics Inc. Reduce -7.0% 1.76% −0.19 RARE Ultragenyx Pharmaceutical Inc. Sold out 0.00% −0.16 KPTI Karyopharm Therapeutics Inc. Sold out 0.00% −0.06 AMLX Amylyx Pharmaceuticals Inc. Reduce -6.3% 0.87% +0.00
Portfolio Buys Q1 2026 → Q2 2026 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2026 % Of Portfolio Change To Portfolio ▼ ALKT Alkami Technology Inc. New 1.77% +1.77 DFTX Definium Therapeutics Inc. Add +43.5% 2.20% +1.45 RLAY Relay Therapeutics Inc. Add +214.2% 1.74% +1.38 CELC Celcuity Inc. New 1.09% +1.09 MBX MBX Biosciences Inc. Add +39.9% 1.83% +0.98 SLN Silence Therapeutics PLC-ADR Add +21.3% 1.37% +0.71 IONS Ionis Pharmaceuticals Inc. Add +132.7% 1.25% +0.64 IMVT Immunovant Inc. Add +17.1% 1.61% +0.54 HRMY Harmony Biosciences Holdings Add +68.5% 1.19% +0.53 ALKS Alkermes PLC Add +18.9% 1.62% +0.51 CUE Cue Biopharma Inc. New 0.48% +0.48 PHVS Pharvaris NV Add +33.4% 1.66% +0.43 DYN Dyne Therapeutics Inc. Add +38.2% 1.29% +0.37 ACRS Aclaris Therapeutics Inc. New 0.34% +0.34 GLUE Monte Rosa Therapeutics Inc. New 0.22% +0.22 ARWR Arrowhead Pharmaceuticals Inc. Add +2.6% 1.73% +0.16 AGIO Agios Pharmaceuticals Inc. Add +24.7% 1.24% +0.15 ACAD Acadia Pharmaceuticals Inc. Add +16.1% 0.69% +0.06 TECX Tectonic Therapeutic Inc. Add +23.8% 0.26% +0.03 PATH Uipath Inc. Class A Add +22.8% 54.76% −0.22
Options Activity Q1 2026 → Q2 2026 Security Type Change vs Q1 2026 Underlying Shares Value ▼ RARE Ultragenyx Pharmaceutical Inc. call New 100,000 $3.3M SLN Silence Therapeutics PLC-ADR call New 300,000 $3.3M KPTI Karyopharm Therapeutics Inc. call Add +400.6% 250,300 $2.4M AGIO Agios Pharmaceuticals Inc. call New 50,000 $1.9M TENX Tenax Therapeutics Inc. call New 75,100 $1.1M AMLX Amylyx Pharmaceuticals Inc. call New 8,500 $153K
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 32 $614.3M PATH, KGEI, AUTL, LYFT, DFTX Q1 2026 34 $508.9M PATH, KGEI, WBD, WK, LYFT Q4 2025 28 $474.3M PATH, KGEI, LYFT, AUTL, CXM Q3 2025 34 $414.0M PATH, KGEI, LYFT, CXM, AUTL Q2 2025 27 $354.0M PATH, KGEI, AUTL, CXM, LYFT Q1 2025 23 $254.6M PATH, KGEI, CXM, INFA, AUTL Q4 2024 Amended 17 $234.4M PATH, KGEI, AUTL, CXM, INFA Q3 2024 13 $222.3M PATH, AUTL, KGEI, TARS, CXM Q2 2024 13 $213.8M PATH, AUTL, KGEI, CXM, BALY Q1 2024 11 $211.9M PATH, AUTL, CXM, KGEI, BALY